IOPtima

About

Funding history · 1 round · $7.2M total

Company Intelligence Q&A

Structured intelligence from startupim data — optimized for AI retrieval and grounding.

When was IOPtima acquired and by which company?

IOPtima was acquired in September 2018 by Chengdu Kanghong Pharmaceutical Group for $56 million.

What was IOPtima's primary product for glaucoma treatment?

IOPtima's flagship product was the IOPtimate, a surgical system that uses CO2 laser technology to reduce internal eye pressure for glaucoma treatment without penetrating the eye.

What was the total funding raised by IOPtima before its acquisition?

IOPtima raised a total of $7.2 million in funding.

Which investors participated in IOPtima's Series B funding round?

In November 2015, IOPtima received Series B funding from investors including Infinity China and Diamond Bio Fund.

When did IOPtima's IOPtiMate system receive regulatory approval in Canada?

IOPtima's IOPtiMate system received regulatory approval in Canada in December 2015.

What new product did IOPtima launch in October 2017?

In October 2017, IOPtima launched Lipitear, a phospholipid microemulsion for ocular surface diseases.

What product did IOPtima launch in July 2017 related to blepharoplasty?

In July 2017, IOPtima launched the iLid CO2 laser kit for blepharoplasty.

When did IOPtima receive European patent approval for its laser system for glaucoma treatment?

IOPtima received European patent approval for its laser system for glaucoma treatment in November 2009.

Sectors & technology

Highlights

Tags